SciFi Futures
← Capabilities
Social & Economic Systems/Infrastructure & scale

Nucleic acid synthesis screening infrastructure

The global chokepoint that checks what DNA people order, and who they are, before synthetic genes are shipped or made on a benchtop device.

State of the art

Wittmann et al. (Science, October 2025) found AI-redesigned homologs of proteins of concern evaded provider screening tools, then raised detection with deployed patches; the US framework that made screening a funding condition is being revised after the May 2025 executive order, and screening is not legally mandated.

What’s blocking it
  • Compliance is voluntary and uneven, so an unscreened provider is a single point of failure
  • Benchtop synthesizers let users bypass commercial ordering entirely
  • Generative protein design keeps producing sequences with low identity to known hazards, so signature-based screening is always catching up
  • No international regime binds providers outside participating jurisdictions

Who’s working on it

  • Launched the Common Mechanism in May 2024, a free open-source screening package that gives any DNA provider a baseline sequence-of-concern check

  • Free cryptographically private screening service that lets providers and benchtop devices check orders without exposing customer sequences

  • Kevin EsveltResearcher
    MIT Media Lab

    Drove the design of privacy-preserving universal screening and the case that benchtop synthesisers outside the voluntary system are the critical gap

  • Eric HorvitzResearcher
    Microsoft Research

    Led the Paraphrase Project, whose October 2025 Science paper showed AI-redesigned protein sequences slipped past screening tools until patches were deployed

  • International Gene Synthesis ConsortiumProgram

    The industry body whose members voluntarily screen sequences and customers; it covers most commercial volume but membership is not mandatory

  • One of the largest synthesis providers, screening all orders and customers, so its practice effectively sets the commercial floor

  • Telesis BioCompany

    Sells benchtop DNA synthesisers, the device class that sits outside provider-level screening and is the main reason coverage is incomplete

What to invest in

KindInvestmentScale
policyLegislation mandating screening and customer verification for all providers and benchtop manufacturers, with a maintained sequences-of-concern list$ < $10M
engineeringShared, continuously red-teamed screening service with hazard-prediction models and audited benchmarking by a standards body$$ $10M – $100M

Depends on

A root node: no prerequisites modeled.

Required by

No other capability builds on this directly.

Sci-fi concepts in reach

Engineered pandemic organismdirect

Sources